Literature DB >> 20212138

Cardiac hypertrophy is not amplified by deletion of cGMP-dependent protein kinase I in cardiomyocytes.

Robert Lukowski1, Sergei D Rybalkin, Florian Loga, Veronika Leiss, Joseph A Beavo, Franz Hofmann.   

Abstract

It has been suggested that cGMP kinase I (cGKI) dampens cardiac hypertrophy. We have compared the effect of isoproterenol (ISO) and transverse aortic constriction (TAC) on hypertrophy in WT [control (CTR)] mice, total cGKI-KO mice, and cGKIbeta rescue mice (betaRM) lacking cGKI specifically in cardiomyocytes (CMs). Infusion of ISO did not change the expression of cGKI in the hearts of CTR mice or betaRM but raised the heart weight by approximately 20% in both. An identical hypertrophic growth response was measured in CMs from CTR mice and betaRM and in isolated adult CMs cultured with or without 1 muM ISO. In both genotypes, ISO infusion induced similar changes in the expression of hypertrophy-associated cardiac genes and significant elevation of serum atrial natriuretic peptide and total cardiac cGMP. No differences in cardiac hypertrophy were obtained by 7-day ISO infusion in 4- to 6-week-old conventional cGKI-KO and CTR mice. Furthermore, TAC-induced hypertrophy of CTR mice and betaRM was not different and did not result in changes of the cGMP-hydrolyzing phosphodiesterase activities in hypertropic hearts or CMs. These results strongly suggest that cardiac myocyte cGKI does not affect the development of heart hypertrophy induced by pressure overload or chronic ISO infusion.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20212138      PMCID: PMC2851748          DOI: 10.1073/pnas.1001360107

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  61 in total

Review 1.  Biochemistry and physiology of cyclic nucleotide phosphodiesterases: essential components in cyclic nucleotide signaling.

Authors:  Marco Conti; Joseph Beavo
Journal:  Annu Rev Biochem       Date:  2007       Impact factor: 23.643

Review 2.  The role of natriuretic peptides in cardioprotection.

Authors:  Toshio Nishikimi; Nobuyo Maeda; Hiroaki Matsuoka
Journal:  Cardiovasc Res       Date:  2005-11-10       Impact factor: 10.787

3.  Npr1-regulated gene pathways contributing to cardiac hypertrophy and fibrosis.

Authors:  Leigh J Ellmers; Nicola J A Scott; Jarkko Piuhola; Nobuyo Maeda; Oliver Smithies; Chris M Frampton; A Mark Richards; Vicky A Cameron
Journal:  J Mol Endocrinol       Date:  2007-02       Impact factor: 5.098

4.  Angiotensin II causes hypertension and cardiac hypertrophy through its receptors in the kidney.

Authors:  Steven D Crowley; Susan B Gurley; Maria J Herrera; Phillip Ruiz; Robert Griffiths; Anil P Kumar; Hyung-Suk Kim; Oliver Smithies; Thu H Le; Thomas M Coffman
Journal:  Proc Natl Acad Sci U S A       Date:  2006-11-07       Impact factor: 11.205

5.  Atrial natriuretic peptide inhibits transforming growth factor beta-induced Smad signaling and myofibroblast transformation in mouse cardiac fibroblasts.

Authors:  Peng Li; Dajun Wang; Jason Lucas; Suzanne Oparil; Dongqi Xing; Xu Cao; Lea Novak; Matthew B Renfrow; Yiu-Fai Chen
Journal:  Circ Res       Date:  2007-11-08       Impact factor: 17.367

6.  Cardiac hypertrophy in transgenic rats expressing a dominant-negative mutant of the natriuretic peptide receptor B.

Authors:  Thomas H Langenickel; Jens Buttgereit; Ines Pagel-Langenickel; Maren Lindner; Jan Monti; Knut Beuerlein; Nidal Al-Saadi; Ralph Plehm; Elena Popova; Jens Tank; Rainer Dietz; Roland Willenbrock; Michael Bader
Journal:  Proc Natl Acad Sci U S A       Date:  2006-03-14       Impact factor: 11.205

7.  Cyclic nucleotide phosphodiesterase PDE1C1 in human cardiac myocytes.

Authors:  Fabrice Vandeput; Sharon L Wolda; Judith Krall; Ryan Hambleton; Lothar Uher; Kim N McCaw; Przemyslaw B Radwanski; Vincent Florio; Matthew A Movsesian
Journal:  J Biol Chem       Date:  2007-08-28       Impact factor: 5.157

Review 8.  Cyclic GMP and protein kinase-G in myocardial ischaemia-reperfusion: opportunities and obstacles for survival signaling.

Authors:  D S Burley; P Ferdinandy; G F Baxter
Journal:  Br J Pharmacol       Date:  2007-08-13       Impact factor: 8.739

9.  Rescue of cGMP kinase I knockout mice by smooth muscle specific expression of either isozyme.

Authors:  Silke Weber; Dominik Bernhard; Robert Lukowski; Pascal Weinmeister; René Wörner; Jörg W Wegener; Nadejda Valtcheva; Susanne Feil; Jens Schlossmann; Franz Hofmann; Robert Feil
Journal:  Circ Res       Date:  2007-09-27       Impact factor: 17.367

Review 10.  Phosphodiesterase type 5: expanding roles in cardiovascular regulation.

Authors:  David A Kass; Hunter C Champion; Joseph A Beavo
Journal:  Circ Res       Date:  2007-11-26       Impact factor: 17.367

View more
  44 in total

1.  Sildenafil and B-type natriuretic peptide acutely phosphorylate titin and improve diastolic distensibility in vivo.

Authors:  Kalkidan Bishu; Nazha Hamdani; Selma F Mohammed; Martina Kruger; Tomohito Ohtani; Ozgur Ogut; Frank V Brozovich; John C Burnett; Wolfgang A Linke; Margaret M Redfield
Journal:  Circulation       Date:  2011-12-05       Impact factor: 29.690

Review 2.  cGMP-dependent protein kinases and cGMP phosphodiesterases in nitric oxide and cGMP action.

Authors:  Sharron H Francis; Jennifer L Busch; Jackie D Corbin; David Sibley
Journal:  Pharmacol Rev       Date:  2010-09       Impact factor: 25.468

3.  Regulation and role of myocyte cyclic GMP-dependent protein kinase-1.

Authors:  David A Kass; Eiki Takimoto
Journal:  Proc Natl Acad Sci U S A       Date:  2010-05-24       Impact factor: 11.205

4.  The role of cGMP-dependent protein kinase in controlling cardiomyocyte cGMP.

Authors:  Sharron H Francis
Journal:  Circ Res       Date:  2010-11-12       Impact factor: 17.367

5.  Myocardial remodeling is controlled by myocyte-targeted gene regulation of phosphodiesterase type 5.

Authors:  Manling Zhang; Eiki Takimoto; Steven Hsu; Dong I Lee; Takahiro Nagayama; Thomas Danner; Norimichi Koitabashi; Andreas S Barth; Djahida Bedja; Kathleen L Gabrielson; Yibin Wang; David A Kass
Journal:  J Am Coll Cardiol       Date:  2010-10-21       Impact factor: 24.094

6.  Cyclic nucleotide phosphodiesterase 1A: a key regulator of cardiac fibroblast activation and extracellular matrix remodeling in the heart.

Authors:  Clint L Miller; Yujun Cai; Masayoshi Oikawa; Tamlyn Thomas; Wolfgang R Dostmann; Manuela Zaccolo; Keigi Fujiwara; Chen Yan
Journal:  Basic Res Cardiol       Date:  2011-10-20       Impact factor: 17.165

Review 7.  Cyclic guanosine monophosphate signaling and phosphodiesterase-5 inhibitors in cardioprotection.

Authors:  Rakesh C Kukreja; Fadi N Salloum; Anindita Das
Journal:  J Am Coll Cardiol       Date:  2012-05-29       Impact factor: 24.094

8.  Molecular Screen Identifies Cardiac Myosin-Binding Protein-C as a Protein Kinase G-Iα Substrate.

Authors:  Robrecht Thoonen; Shewit Giovanni; Suresh Govindan; Dong I Lee; Guang-Rong Wang; Timothy D Calamaras; Eiki Takimoto; David A Kass; Sakthivel Sadayappan; Robert M Blanton
Journal:  Circ Heart Fail       Date:  2015-10-18       Impact factor: 8.790

9.  PDE1C deficiency antagonizes pathological cardiac remodeling and dysfunction.

Authors:  Walter E Knight; Si Chen; Yishuai Zhang; Masayoshi Oikawa; Meiping Wu; Qian Zhou; Clint L Miller; Yujun Cai; Deanne M Mickelsen; Christine Moravec; Eric M Small; Junichi Abe; Chen Yan
Journal:  Proc Natl Acad Sci U S A       Date:  2016-10-20       Impact factor: 11.205

Review 10.  Therapeutic potential of PDE modulation in treating heart disease.

Authors:  Walter Knight; Chen Yan
Journal:  Future Med Chem       Date:  2013-09       Impact factor: 3.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.